Long non-coding RNAs (lncRNAs) are a group greater than 200 nucleotides in length.
| INTRODUCTION
It has been estimated that approximately 2% of the human genome is transcribed into protein-coding RNAs, whereas the remaining transcribed regions give rise to non-coding RNAs (ncRNAs), [1] [2] [3] which can be separated into two major groups: small/short ncRNAs (<200 nucleotides) and long ncRNAs (>200 nucleotides; lncRNAs). [4] [5] [6] [7] [8] Initially regarded as a consequence of transcriptional noise or promiscuous RNA polymerase II activity, an increasing number of studies have now demonstrated that lncRNAs play important roles in a repertoire of biological processes, including development, cell differentiation, proliferation, apoptosis and invasion through controlling gene expression through different mechanisms, including (1) chromatin remodelling;
(2) regulation of recruitment of transcription factors and co-activators (cis-acting); (3) negatively regulation of RNA polymerase II activity; (4) alternative splicing of pre-mRNAs; (5) regulation of mRNA stability; and (6) sequestration of microRNAs. [9] [10] [11] [12] [13] Pertinent to chromatin remodelling, lncRNAs could form extensive networks of ribonucleoprotein complexes with numerous chromatin regulators, such as Polycombgroup proteins and G9a, and then target these complexes to specific locations in the genome. 14 lncRNAs could also interact widely to regulate physiological processes (e.g. apoptosis) in an orchestrated manner. 15 The detailed mechanisms by which lncRNAs regulate gene expression at the transcriptional and post-transcriptional levels have been extensively reviewed by other investigators. [16] [17] [18] The abnormal expression of lncRNAs has been documented in 
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Among all cancer-related lncRNAs, the taurine upregulated gene 1 (TUG1) is a rising star. [36] [37] [38] Increasing evidences have shown that TUG1 plays important roles in a number of human cancers, such as hepatocellular carcinoma, osteosarcoma, glioma and bladder cancer. [39] [40] [41] [42] In this review, we summarize current evidences concerning the role of TUG1 in the development and progression of cancers (Table 1) .
| STRUCTURAL CHARACTERIZATION OF TUG1
TUG1 is a 7.1-kb lncRNA and was first identified in a genomic scan for genes upregulated in response to taurine treatment in devel- 
| TUG1 IN HUMAN CANCERS

| B-cell malignancies
Isin et al. 37 measured the levels of five selected lncRNAs (LincRNA-p21, TUG1, HOTAIR, MALAT1 and GAS5) by real-time PCR using cDNA synthesized from plasma RNAs isolated from chronic lymphocytic leukaemia and multiple myeloma patients. The investigators showed that LincRNA-p21 was the only lncRNA displaying significant upregulation in chronic lymphocytic leukaemia patients, while other four lncRNAs, including TUG1, showed significant downregulation in multiple myeloma patients as compared with healthy subjects.
| Non-small cell lung cancer
Zhang et al. 38 demonstrated that TUG1 was downregulated in NSCLC tissues as compared with non-tumour tissues. The lower TUG1 expression was correlated with poorer overall survival, larger tumour size and higher tumour-node-metastasis (TNM) staging.
Moreover, TUG1 expression could act as an independent predictor for overall survival of NSCLC patients. Mechanistically, TUG1 was directly induced by p53. Knock-down of TUG1 increased NSCLC cell proliferation in vitro and in vivo and promoted the expression of homeobox B7 (HOXB7), an oncogenic homeo domain protein.
These data suggested that TUG1 is a tumour-suppressive lncRNA in NSCLC.
| Oesophageal squamous cell carcinoma
Xu et al. 57 showed that TUG1 was upregulated in the oesophageal squamous cell carcinoma (ESCC) tissues compared to adjacent non-tumour tissues. Higher expression of TUG1 was also correlated with upper segment and family history of oesophageal cancer.
Moreover, knock-down of TUG1 suppressed ESCC cell migration Osteosarcoma Up ALP Oncogene (30) and proliferation, accompanied by inhibition of cell cycle progression.
These results suggested that TUG1 is a potential oncogenic lncRNA in ESCC.
| Glioma
Liu et al. 41 
| Bladder cancer
Tan et al. 
| Hepatocellular carcinoma
Huang et al. 
| Osteosarcoma
Ma et al. 40 showed that TUG1 was upregulated in osteosarcoma tissues compared to adjacent non-tumour tissues. TUG1 expression was also associated with the need of post-operative chemotherapy, tumour size and Enneking surgical stage. The higher level of TUG1 was correlated with poorer prognosis, including shortened overall and progression-free survival, independent of other clinicopathological parameters. The expression of TUG1 in plasma was decreased post-operation and the resurgence of TUG1 expression signalled disease recurrence. As a biomarker, TUG1 was superior to ALP (alkaline phosphatase) in distinguishing cases with osteosarcoma from healthy controls.
| Colorectal cancer
Sun et al. 
| CONCLUDING REMARKS AND FUTURE PERSPECTIVES
TUG1, upregulated in multiply human cancers (except NSCLC and multiple myeloma), is a newly characterized oncogene. TUG1 can promote cancer cell proliferation, migration and invasion, and suppress apoptosis. TUG1 mediates its biological functions at least in part through chromatin remodelling and sequestration of microRNAs.
However, the detailed downstream molecular mechanisms remain to be elucidated. Emerging technologies, such as high-throughput identification of binding partners and integrative analysis of omics data, will help delineate the downstream pathways mediated by TUG1. The upstream event underlying TUG1 deregulation in each cancer type may also be different and needs further characterization. As a potential prognostic marker, higher TUG1 levels are associated with poorer clinicopathological parameters, such as survival, in HCC, osteosarcoma and CRC. However, validating the prognostic significance of TUG1 in larger cohort is mandatory. TUG1 is also a viable drug target but the effect of systemic inhibition of TUG1 remains unknown. With more efforts put forth to the study of lncRNAs, especially TUG1, it is hopeful that TUG1 will eventually achieve clinical utility.
